Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDIX II HER2
2018-004457-24Phase 2Terminated
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, trastuzumab and pertuzumab in breast cancer (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Pathologic complete response rate. Started Jan 2019; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-004457-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004457-24.